Accuray reported gains in its preliminary financial results for the first quarter of the 2022 fiscal year, with the company citing an increase in gross orders as a growth driver.
The company said its revenue this quarter (end-September 30) was $107.4 million. Compared with the $85.3 million reported at the same time in 2020, this represents a 26% year-over-year growth. Accuray also saw gross orders of $70 million for the quarter, an increase of 39% from the same period in 2020.
As a result, the company updated its expected revenue for the full fiscal year to range between $420 million and $427 million.
Accuray said it expects the company's net loss to be between $1 million to $2 million.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&fit=crop&h=100&q=70&w=100)
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
